Patents Assigned to Horizon Pharma USA, Inc.
-
Patent number: 9801824Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.Type: GrantFiled: July 12, 2016Date of Patent: October 31, 2017Assignees: Pozen Inc., Horizon Pharma USA, Inc.Inventors: Brian Ault, Everardus Orlemans, John R. Plachetka, Mark Sostek
-
Publication number: 20170071861Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 12, 2016Publication date: March 16, 2017Applicants: POZEN INC., HORIZON PHARMA USA, INC.Inventors: Brian AULT, Everardus ORLEMANS, John R. PLACHETKA, Mark SOSTEK
-
Patent number: 9393208Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.Type: GrantFiled: December 28, 2015Date of Patent: July 19, 2016Assignees: Pozen Inc., Horizon Pharma USA, Inc.Inventors: Brian Ault, Everardus Orlemans, John R. Plachetka, Mark Sostek
-
Publication number: 20160166558Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.Type: ApplicationFiled: February 23, 2016Publication date: June 16, 2016Applicants: POZEN INC., HORIZON PHARMA USA, INC.Inventors: Brian AULT, Clara HWANG, Everardus Orlemans, John R. PLACHETKA, Mark SOSTEK
-
Publication number: 20160106678Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 28, 2015Publication date: April 21, 2016Applicants: POZEN INC., HORIZON PHARMA USA, INC.Inventors: Brian AULT, Everardus ORLEMANS, John R. PLACHETKA, Mark SOSTEK
-
Patent number: 9220698Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.Type: GrantFiled: September 3, 2009Date of Patent: December 29, 2015Assignees: Pozen Inc., Horizon Pharma USA, Inc.Inventors: Brian Ault, Mark Sostek, Everardus Orlemans, John R. Plachetka
-
Publication number: 20150202193Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.Type: ApplicationFiled: January 9, 2015Publication date: July 23, 2015Applicants: POZEN INC., HORIZON PHARMA USA, INC.Inventors: Brian AULT, Clara HWANG, Everardus Orlemans, John R. PLACHETKA, Mark SOSTEK
-
Patent number: 8945621Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.Type: GrantFiled: June 24, 2010Date of Patent: February 3, 2015Assignees: Pozen Inc., Horizon Pharma USA, Inc.Inventors: Brian Ault, Clara Hwang, Everardus Orlemans, John R Plachetka, Mark Sostek
-
Publication number: 20140186439Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Type: ApplicationFiled: August 6, 2013Publication date: July 3, 2014Applicant: HORIZON PHARMA USA, INC.Inventors: Jerry Xu, George F. Tidmarsh
-
Publication number: 20140066485Abstract: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine, in admixture, is administered three times per day.Type: ApplicationFiled: February 15, 2013Publication date: March 6, 2014Applicant: HORIZON PHARMA USA, INC.Inventor: Horizon Pharma USA, Inc.
-
Publication number: 20140017321Abstract: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.Type: ApplicationFiled: February 4, 2013Publication date: January 16, 2014Applicant: HORIZON PHARMA USA, INC.Inventor: HORIZON PHARMA USA, INC.
-
Patent number: 8501228Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Type: GrantFiled: September 14, 2012Date of Patent: August 6, 2013Assignee: Horizon Pharma USA, Inc.Inventors: Jerry Xu, George F. Tidmarsh
-
Patent number: 8449910Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Type: GrantFiled: September 14, 2012Date of Patent: May 28, 2013Assignee: Horizon Pharma USA, Inc.Inventors: Jerry Xu, George F. Tidmarsh
-
Publication number: 20130078287Abstract: Pharmaceutical compositions of a H2 receptor antagonist and ibuprofen are provided herein. The compositions comprise, e.g., a core and a shell separated by a barrier layer, bilayered or trilayered compositions, or liquid formulations. Also provided are methods of making the pharmaceutical compositions, and methods of treatment comprising administering the pharmaceutical compositions.Type: ApplicationFiled: November 19, 2012Publication date: March 28, 2013Applicant: Horizon Pharma USA, Inc.Inventor: Horizon Pharma USA, Inc.
-
Patent number: 8318202Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Type: GrantFiled: February 23, 2012Date of Patent: November 27, 2012Assignee: Horizon Pharma USA, Inc.Inventors: Jerry Xu, George F. Tidmarsh
-
Patent number: 8309127Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Type: GrantFiled: February 23, 2012Date of Patent: November 13, 2012Assignee: Horizon Pharma USA, Inc.Inventors: Jerry Xu, George F. Tidmarsh
-
Patent number: 8067451Abstract: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.Type: GrantFiled: July 17, 2007Date of Patent: November 29, 2011Assignee: Horizon Pharma USA, Inc.Inventors: George Tidmarsh, Barry L. Golombik, Puneet Sharma
-
Patent number: 8067033Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Type: GrantFiled: November 26, 2008Date of Patent: November 29, 2011Assignee: Horizon Pharma USA, Inc.Inventors: Jerry Xu, George Tidmarsh
